Mechanisms of lapatinib resistance in HER2-driven breast cancer.

@article{DAmato2015MechanismsOL,
  title={Mechanisms of lapatinib resistance in HER2-driven breast cancer.},
  author={Valentina D'Amato and Lucia Raimondo and Luigi Formisano and Mario Alberto Giuliano and Sabino De Placido and Roberta Tagliari da Rosa and Roberto Bianco},
  journal={Cancer treatment reviews},
  year={2015},
  volume={41 10},
  pages={
          877-83
        }
}
Targeted therapies have been approved for various malignancies but the acquisition of resistance remains a substantial challenge in the clinical management of advanced cancers. Twenty-five per cent of breast cancers overexpress ErbB2/HER2, which confers a more aggressive phenotype and is associated with a poor prognosis. HER2-targeting therapies (trastuzumab, pertuzumab, TDM1 and lapatinib) are available, but a significant fraction of HER2-positive breast cancers eventually relapse or progress… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

Similar Papers

Loading similar papers…